Verastem: A Real Pancreatic Cancer Drug, Arriving Second (NASDAQ:VSTM)
· seekingalpha.com
Verastem (VSTM) stock outlook: Hold rating as VS-7375 KRAS G12D data shows promise, but dilution, competition, and cash burn persist—read now.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...